SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Curtis, D. J. Articles by Begley, C. G. Search for Related Content PubMed PubMed Citation Articles by Curtis, D. J. Articles by Begley, C. G. Related Collections Hematopoiesis and Stem Cells Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Recombinant Soluble Interleukin-11 (IL-11) Receptor -Chain Can Act as an IL-11 Antagonist David J. Curtis, Douglas J. Hilton, Bronwyn Roberts, Leecia Murray, Nicos Nicola, and C. Glenn Begley From the Walter and Eliza Hall Institute of Medical Research, and The Co-operative Research Centre for Cellular Growth Factors, and Rotary Bone Marrow Research Laboratory, Royal Melbourne Hospital, Victoria, Australia. We have expressed a soluble N-glycosylated form of the murine interleukin-11 (IL-11) receptor -chain (sIL-11R) and examined signaling in cells expressing the gp130 molecule. In the presence of gp130 but not the transmembrane IL-11R, the sIL-11R mediated IL-11-dependent differentiation of M1 leukemic cells and proliferation in Ba/F3 cells. Early intracellular events stimulated by the sIL-11R including phosphorylation of gp130, STAT 3, and SHP-2 were similar to signaling through the transmembrane IL-11R. IL-11 bound to sIL-11R with low affinity (kd 10 to 50 nmol/L). Binding of sIL-11R to gp130 was IL-11 dependent with intermediate affinity (kd 1.5 to 3.0 nmol/L). However, the concentration of IL-11 required for signaling through the sIL-11R was 10- to 20-fold greater than that required for cells expressing the transmembrane IL-11R and gp130 in the absence of sIL-11R. Furthermore, the sIL-11R was capable of antagonizing the activity of IL-11 when tested on cells expressing the transmembrane IL-11R and gp130. We propose that the observed IL-11 antagonism by the sIL-11R may depend on limiting numbers of gp130 molecules on cells already expressing the transmembrane IL-11R. Blood, Vol. 90 No. 11 (December 1), 1997: pp. 4403-4412 © 1997 by The American Society of Hematology. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF] D. J. Bernard and T. K. Woodruff Inhibin Binding Protein in Rats: Alternative Transcripts and Regulation in the Pituitary across the Estrous Cycle Mol. Endocrinol., April 1, 2001; 15(4): 654 - 667. [Abstract] [Full Text] J. Audet, C. L. Miller, S. Rose-John, J. M. Piret, and C. J. Eaves Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells PNAS, February 13, 2001; 98(4): 1757 - 1762. [Abstract] [Full Text] [PDF] C. J. Auernhammer and S. Melmed Leukemia-Inhibitory Factor--Neuroimmune Modulator of Endocrine Function Endocr. Rev., June 1, 2000; 21(3): 313 - 345. [Abstract] [Full Text] M. Peters, A. M. Muller, and S. Rose-John Interleukin-6 and Soluble Interleukin-6 Receptor: Direct Stimulation of gp130 and Hematopoiesis Blood, November 15, 1998; 92(10): 3495 - 3504. [Full Text] [PDF]

	Copyright © 1997 by American Society of Hematology         Online ISSN: 1528-0020